

## Peter Webse

---

**From:** ASXMarket.AnnouncementsOffice@asx.com.au  
**Sent:** Tuesday, 28 March 2017 1:50 PM  
**To:** ASXMarket.AnnouncementsOffice@asx.com.au  
**Subject:** Confirmation of Release - RAC - Appendix 3Y-Bill Garner  
**Attachments:** 1659260.pdf

ASX confirms the release to the market of Doc ID: 1659260 as follows:

Release Time: 28-MAR-2017 16:50:13

ASX Code: RAC

Related ASX Codes:

Announcement Title: Appendix 3Y-Bill Garner

ASX Market Announcement Office | ASX Limited

20 Bridge Street, Sydney, NSW 2000

INTL:+61 2 8298 8044 | T: 1800 021 965 | F: 1300 135 638 MAOgroup@asx.com.au | www.asx.com.au Please consider the environment before printing this email

The information in this email is confidential, it may also be privileged and is intended for the exclusive use of the addressee(s). If you have received this email in error, please do not distribute it, notify me and destroy the original message and all copies. The unauthorised use of this email may result in liability for breach of confidentiality, privilege or copyright. E-mail transmissions cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete or contain viruses. The sender does not accept liability for errors or omissions in the contents of this message which arise as a result of e-mail transmission.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Race Oncology Limited</b>
<b>ABN</b>	61 149 318 749

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>William James Garner</b>
<b>Date of last notice</b>	<b>12 July 2016</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	1. Direct 2. Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. Update Pharma Inc – Director Related Entity
<b>Date of change</b>	27 March 2017
<b>No. of securities held prior to change</b>	1. Nil 2. 15,000,000 Ordinary Shares escrowed until 13/7/2018 10,000,000 Performance Shares escrowed until 13/7/2018.
<b>Class</b>	1. Ordinary Shares
<b>Number acquired</b>	1. 25,000
<b>Number disposed</b>	-
<b>Value/Consideration includes brokerage/gst</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$5,090.00

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 25,000 Ordinary Shares</li> <li>2. 15,000,000 Ordinary Shares escrowed until 13/7/2018</li> <li>10,000,000 Performance Shares escrowed until 13/7/2018</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On-market purchase.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.